#18: CHA2DS2-VASc scoring and anticoagulation for silent atrial fibrillation, race and renin-angiotensin system inhibition in HFrEF, V142I transthyretin gene variant and cardiovascular health

In less than 15 minutes, Medmastery’s Cardiology Digest will give you the low-down on some of the most compelling studies in cardiology that clinicians with an interest in cardiovascular health need to know about. STUDY #1: We kick things off by exploring exactly where the CHA2DS2-VASc score fits into anticoagulation decisions in patients with silent atrial fibrillation. Building on the main findings from the ARTESiA and NOAH-AFNET 6 trials, this study sparks a thought-provoking discussion on the future of risk stratification. Tune in to hear insights that could shape your clinical practice.  Lopes, RD, Granger, CB, Wojdyla, DM, et al. 2024. Apixaban versus aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: Insights from ARTESiA. J Am Coll Cardiol. In Press, Journal Pre-proof. (https://doi.org/10.1016/j.jacc.2024.05.002) STUDY #2: Next, we break down misconceptions surrounding race and treatment efficacy in heart failure with reduced ejection fraction. This study shines a light on the impacts of renin-angiotensin system inhibition across different racial groups. See how these findings challenge the outdated genetic constructs of race, and what they mean for your approach to patient care. Shen, L, Lee, MM, Jhund, PS, et al. 2024. Revisiting race and the benefit of RAS blockade in heart failure: A meta-analysis of randomized clinical trials. JAMA. 24: 2094–2104. (https://doi.org/10.1001/jama.2024.6774) STUDY #3: Finally, we turn our focus to the V142I transthyretin gene variant, to evaluate its impacts on cardiovascular health within the U.S. Black population. This research not only highlights the need for targeted genetic screening but also raises important questions about the accessibility of costly treatments for transthyretin amyloidosis. Selvaraj, S, Claggett, B, Shah, SH,  et al. 2024. Cardiovascular burden of the V142I transthyretin variant. JAMA. 21: 1824–1833. (https://doi.org/10.1001/jama.2024.4467) Maurer, MS, Miller, EJ, Ruberg, FL, et al. 2024. Addressing health disparities—The case for variant transthyretin cardiac amyloidosis grows stronger. JAMA. 21: 1809–1811. (https://doi.org/10.1001/jama.2024.2868) Yancy, CW. 2024. Heart failure in African American individuals, Version 2.0. JJAMA. 21: 1807–1808. (https://doi.org/10.1001/jama.2024.5217) Don't miss out on this rich discussion that promises to enhance your understanding and expertise!  Learn more with these courses: Medical Treatment of Heart Failure (2 CME) Atrial Fibrillation Management Essentials (1 CME) Get a Basic or Pro account, or, get a Trial account. Show notes: Visit us at  https://www.medmastery.com/podcasts/cardiology-podcast.

Om Podcasten

In 15 minutes or less, keep up to date on the latest studies and advancements in cardiology with the award-winning, leading clinical skills training platform, Medmastery! We’re recommended by the British Medical Association, and hundreds of thousands of clinicians around the world trust us to simplify complex information. We make it bite-sized, and easy to fit into your daily routine! In the complex and rapidly evolving field of cardiology, with new treatments and technologies emerging all the time, it can be tough to keep up with all the papers published on a daily basis. That's where our Cardiology Digest comes in. Our cardiology experts select the most important papers. Then we break them down into easy-to-understand, digestible nuggets that help you stay informed and empowered to make the right decisions for your patients. From heart disease to arrhythmias, we cover a range of topics—including cutting-edge diagnostic tools and treatment options—that are relevant to the field. So, if you're looking for a simple, accessible way to stay up to date with the latest trends and advancements in cardiology and medicine, tune in to Medmastery's Cardiology Digest! Visit us at www.medmastery.com!